Oyan Uluç, B. Et Al. 2018. Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors. American Society of Clinical Oncology (ASCO) Annual Meeting , (Illinois, United States Of America), 2436.

Oyan Uluç, B., Sönmez, Ö., Yazar, A., & Teomete, M., (2018). Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors . American Society of Clinical Oncology (ASCO) Annual Meeting (pp.2436). Illinois, United States Of America

Oyan Uluç, BAŞAK Et Al. "Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors," American Society of Clinical Oncology (ASCO) Annual Meeting, Illinois, United States Of America, 2018

Oyan Uluç, BAŞAK O. Et Al. "Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors." American Society of Clinical Oncology (ASCO) Annual Meeting , Illinois, United States Of America, pp.2436, 2018

Oyan Uluç, B. Et Al. (2018) . "Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors." American Society of Clinical Oncology (ASCO) Annual Meeting , Illinois, United States Of America, p.2436.

@conferencepaper{conferencepaper, author={BAŞAK OYAN ULUÇ Et Al. }, title={Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors}, congress name={American Society of Clinical Oncology (ASCO) Annual Meeting}, city={Illinois}, country={United States Of America}, year={2018}, pages={2436} }